SAMR

FDA Approves Eli Lilly's Onswik – Once‑Weekly Basal Insulin for Adults With Type 2 Diabetes
CompanyDrug

FDA Approves Eli Lilly’s Onswik – Once‑Weekly Basal Insulin for Adults With Type 2 Diabetes

Eli Lilly and Company (NYSE: LLY) announced that the U.S. FDA has approved Onswik (insulin efsitora alfa‑gobe), a once‑weekly basal insulin indicated, along with diet and exercise, to control high…

AstraZeneca to Invest USD 2 Billion in Summit Therapeutics – Clinical Collaboration Anchored on Ivonescimab and Claudin 18.2 ADC Sone‑Ve

AstraZeneca to Invest USD 2 Billion in Summit Therapeutics – Clinical Collaboration Anchored on Ivonescimab and Claudin 18.2 ADC Sone‑Ve

AstraZeneca Submits FDA NDA for Orpathys–Tagrisso Combination – Targeting MET‑Altered NSCLC After EGFR TKI Failure

AstraZeneca Submits FDA NDA for Orpathys–Tagrisso Combination – Targeting MET‑Altered NSCLC After EGFR TKI Failure

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
Legal / IPPolicy / Regulatory

China’s Seven Ministries Issue Revised Pharmaceutical Representative Management Measures to Combat Commercial Bribery and Strengthen Industry Oversight

China Issues Whistleblower Incentives for Drug and Medical Device Safety Violations
Policy / Regulatory

China Issues Whistleblower Incentives for Drug and Medical Device Safety Violations

Legal / IPPolicy / Regulatory

China’s SAMR Proposes Antitrust Guidelines to Regulate Pharmaceutical Industry

Policy / Regulatory

China Unveils Comprehensive Plan to Tackle Unhealthy Practices in Pharma and Healthcare

Policy / Regulatory

Hubei Province Issues Anti-Commercial Bribery Guidelines for Medical Industry

Company

Shanghai Pharmaceuticals Hit with Anti-Monopoly Fine by Shanghai Market Supervision Bureau

Policy / Regulatory

NMPA Pilots Priority Review for Rare Disease Formula Foods, Aims to Reduce Approval Time

Policy / Regulatory

SAMR and Nine Ministries Tighten Regulations on Forums and Conferences in China

Show More